Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 196

Sort by

Sort Order Select

Journal Articles

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

Blood (2025) 146 (Supplement 1): 127.

https://doi.org/10.1182/blood-2025-127

Published: 2025

Journal Articles

An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 5481.

https://doi.org/10.1182/blood-2025-5481

Published: 2025

Journal Articles

Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis

Blood (2025) 146 (Supplement 1): 3733.

https://doi.org/10.1182/blood-2025-3733

Published: 2025

Journal Articles

Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE

Roch Houot, Pablo Arija, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Cedric Portugues, Catherine Thieblemont, Markqayne Ray, Yin Yang, Sante Cundari, Camille Linot, Divyesh Mistry, Martijn Simons, Anna Gittfried, François Lemonnier

Blood (2025) 146 (Supplement 1): 3714.

https://doi.org/10.1182/blood-2025-3714

Published: 2025

Journal Articles

A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

Blood (2025) 146 (Supplement 1): 3883.

https://doi.org/10.1182/blood-2025-3883

Published: 2025

Journal Articles

BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with Relapsed/Refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the Phase 1 dose escalation study

Blood (2025) 146 (Supplement 1): 480.

https://doi.org/10.1182/blood-2025-480

Published: 2025

Journal Articles

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.

Blood (2025) 146 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2025-1958

Published: 2025

Journal Articles

Epitranscriptomic signatures define prognosis and therapeutic vulnerabilities in large B-cell lymphoma

Caroline Molinaro, Jeanne Loiseau, Andrea Romero, Aurore Attina, Sonia Garcia Llorens, Alexandre David, Christophe Hirtz, Denis Coulomb, Guillaume Cartron, Ludovic Gabellier, Jerome Moreaux, Charles Herbaux

Blood (2025) 146 (Supplement 1): 5312.

https://doi.org/10.1182/blood-2025-5312

Published: 2025

Journal Articles

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

Gabriel Brisou, Aurelien Belot, Emmanuel Bachy, Herve Ghesquieres, François-Xavier Gros, Krimo Bouabdallah, Guillaume Cartron, Roberta Di Blasi, Roch Houot, Cedric Rossi, Amandine Durand, Fabien Le Bras, Corinne Haioun, Thomas Gastinne, Remy Dulery, Pierre Bories, Fabrice Jardin, Blandine Guffroy, Luc-Matthieu Fornecker, Cristina Castilla-Llorente, Gandhi Damaj, Franck Morschhauser, Michael Loschi, Stephanie Guidez, Choquet Sylvain, Aline Schmidt, Laurianne Drieu La Rochelle, Marie-Thérèse Rubio, Sylvain Carras, Jacques-Olivier Bay, Adrien Chauchet, Magalie Joris, Ludovic Fouillet, Laure Lebras, Julie Abraham, Fontanet Bijou, Olivier Hermine, Antoine Bonnet, Justine Decroocq, Sandy Amorim, Nadine Morineau, Pauline Lionne, Sophie Dennetiere, Laura Herbreteau, Bernard Drenou, Launay Vincent, Gaelle Olivier, Gaëlle Labouré, Olivier Fitoussi, Christophe Fruchart, Cecile Leyronnas, Fanny Cherblanc, Elodie Gat, Benoit Tessoulin

Blood (2025) 146 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2025-2764

Published: 2025

Journal Articles

CRISPR-ko screen identifies RARα inhibition as a strategy to increase CD38 expression in multiple myeloma and potentiate anti-CD38 therapy.

Laura Alibert, Sara scaramuzzino, Camille Soun, Guilhem Requirand, Nicolas Robert, Laure Vincent, Charles Herbaux, Guillaume Cartron, Caroline Bret, Sandrine Roulland, Jerome Moreaux, Sara Ovejero

Blood (2025) 146 (Supplement 1): 2146.

https://doi.org/10.1182/blood-2025-2146

Published: 2025

Journal Articles

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial

John Seymour, Andrew Aw, Vincent Ribrag, Guillaume Cartron, Arnon Kater, Ki-Seong Eom, Alan Skarbnik, Alessandra Tedeschi, Malgorzata Wach, Jing-Zhou Hou, Arpad Illes, Batul Suterwala, Jiefen Munley, Ellie John, Toshifumi Fujimori, Jennifer Brown

Blood (2025) 146 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2025-2118

Published: 2025

Journal Articles

Next-generation tumor-specific anti-CD30 ADC as a new therapy in hemato-oncology

Johanna Marines, Baptiste Gouyou, Lindsay Alcaraz, Margaux Maurel, Adrien Laroche, Vincent Roux-Portalez, Tristan Mangeat, Guillaume Cartron, Bernard Pau, Anne Chevrel

Blood (2025) 146 (Supplement 1): 1519.

https://doi.org/10.1182/blood-2025-1519

Published: 2025

Journal Articles

Longitudinal single-cell profiling of the bone marrow heterogeneity identifies the T-cell niche supporting cancer persister cells in follicular lymphoma

Karin Tarte, Alicia Beyou, Simon Leonard, Joelle DULONG, Stephane Rodriguez, Noushin Mossadegh-Keller, Gabriel Brisou, Charles BROTTIER, Luc Xerri, Bertrand Nadel, Camille Laurent, Guillaume Cartron, Sandrine Roulland

Blood (2025) 146 (Supplement 1): 553.

https://doi.org/10.1182/blood-2025-553

Published: 2025

Journal Articles

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

Paolo Ghia, Barbara Eichhorst, Tomasz Wrobel, Inci Alacacıoğlu, Ana Rita da Fonseca, Dennis Carney, Guillaume Cartron, Alina Gerrie, Don Stevens, Marianne de Borja, Toshifumi Fujimori, Ellie John, L. Alex Liggett, Gary De Jesus, Veerendra Munugalavadla, Jennifer Brown

Blood (2025) 146 (Supplement 1): 3898.

https://doi.org/10.1182/blood-2025-3898

Published: 2025

Journal Articles

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Blood (2025) 146 (Supplement 1): 467.

https://doi.org/10.1182/blood-2025-467

Published: 2025

Journal Articles

CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry

Blood (2025) 146 (Supplement 1): 1012.

https://doi.org/10.1182/blood-2025-1012

Published: 2025

Journal Articles

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Blood (2025) 146 (Supplement 1): 956.

https://doi.org/10.1182/blood-2025-956

Published: 2025

Journal Articles

Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results.

Blood (2025) 146 (Supplement 1): 5923.

https://doi.org/10.1182/blood-2025-5923

Published: 2025

Journal Articles

Real-world data of lisocabtagene maraleucel as second line therapy for patients with large B-cell lymphoma: Updated Results of the french descar-T registry by lysa

Gabriel Brisou, Roch Houot, Roberta Di Blasi, Guillaume Cartron, Franck Morschhauser, Emmanuel Bachy, Cristina Castilla-Llorente, Axel André, Michael Loschi, François-Xavier Gros, Pierre Bories, Blandine Guffroy, Eve Gehlkopf, Elodie Gat, Benoit Tessoulin

Blood (2025) 146 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2025-4541

Published: 2025

Journal Articles

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

Blood (2025) 146 (8): 913–925.

https://doi.org/10.1182/blood.2024027727

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry

An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis

Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE

A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with Relapsed/Refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the Phase 1 dose escalation study

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.

Epitranscriptomic signatures define prognosis and therapeutic vulnerabilities in large B-cell lymphoma

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

CRISPR-ko screen identifies RARα inhibition as a strategy to increase CD38 expression in multiple myeloma and potentiate anti-CD38 therapy.

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial

Next-generation tumor-specific anti-CD30 ADC as a new therapy in hemato-oncology

Longitudinal single-cell profiling of the bone marrow heterogeneity identifies the T-cell niche supporting cancer persister cells in follicular lymphoma

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results.

Real-world data of lisocabtagene maraleucel as second line therapy for patients with large B-cell lymphoma: Updated Results of the french descar-T registry by lysa

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only